Payment overview · 2025
General Payments
$10,003.70
85 reported records · 21 companies
Healthcare provider profile · identity verified
Nick Abedi, MD
Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery · LEXINGTON, KY · NPI 1366605271
Verified facts
What the public records show
CMS Open Payments records show Nick Abedi, MD received $10,003.70 in general payments during 2025 across 85 reported records.
Penumbra, Inc. accounted for 29.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $2,983.93 | 29.8% | 9 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $2,644.62 | 26.4% | 16 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $1,526.24 | 15.3% | 13 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $596.61 | 6.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$525.54 | 5.2% | 9 | 2025 |
| Vesalio, Inc. | Unresolved — no canonical attribution shown | $500.00 | 5.0% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $268.14 | 2.7% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $249.38 | 2.5% | 4 | 2025 |
| Becton, Dickinson and Company | Unresolved — no canonical attribution shown | $109.72 | 1.1% | 2 | 2025 |
| Imperative Care, Inc | Unresolved — no canonical attribution shown | $101.83 | 1.0% | 4 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $101.47 | 1.0% | 4 | 2025 |
| Royal Biologics, Inc. | Unresolved — no canonical attribution shown | $65.98 | 0.7% | 1 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $64.45 | 0.6% | 4 | 2025 |
| ASAHI INTECC USA, INC. | Unresolved — no canonical attribution shown | $59.18 | 0.6% | 1 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $53.01 | 0.5% | 2 | 2025 |
| Cook Medical LLC | Unresolved — no canonical attribution shown | $50.22 | 0.5% | 5 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $26.62 | 0.3% | 1 | 2025 |
| Avita Medical Americas, LLC | Unresolved — no canonical attribution shown | $25.18 | 0.2% | 1 | 2025 |
| Surmodics, Inc. | Unresolved — no canonical attribution shown | $18.41 | 0.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.59 | 0.2% | 1 | 2025 |
| Bolton Medical Inc | Unresolved — no canonical attribution shown | $16.58 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $5,375.72 | 75 |
| Travel and Lodging | $4,127.98 | 9 |
| Consulting Fee | $500.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $2,983.93 | 9 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $1,491.72 | 4 | 2025 |
Source payment records
|
|||||
| GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis Normalized: gore excluder thoracoabdominal branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $1,343.47 | 8 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $676.39 | 7 | 2025 |
Source payment records
|
|||||
| Alto Abdominal Stent Graft System Normalized: alto abdominal stent graft system |
Device | Endologix LLC | $596.61 | 1 | 2025 |
Source payment records
|
|||||
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $373.47 | 4 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $291.35 | 2 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $249.38 | 4 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $185.16 | 3 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $185.16 | 3 | 2025 |
Source payment records
|
|||||
| GORE TAG Conformable Thoracic Endoprosthesis Normalized: gore tag conformable thoracic endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $182.77 | 5 | 2025 |
Source payment records
|
|||||
| Varithena Administration Pack Normalized: varithena administration pack |
Device | Boston Scientific Corporation | $165.06 | 2 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Becton, Dickinson and Company | $109.72 | 2 | 2025 |
Source payment records
|
|||||
| SYMPHONY CATHETER Normalized: symphony catheter |
Device | Imperative Care, Inc | $101.83 | 4 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $84.84 | 3 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $82.35 | 2 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Neuroprotection System Normalized: enroute transcarotid neuroprotection system |
Device | Boston Scientific Corporation | $77.27 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $64.45 | 4 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $64.45 | 4 | 2025 |
Source payment records
|
|||||
| Asahi Peripheral Vascular Wires Normalized: asahi peripheral vascular wires |
Device | ASAHI INTECC USA, INC. | $59.18 | 1 | 2025 |
Source payment records
|
|||||
| AZUR CX DETACHABLE Normalized: azur cx detachable |
Device | Terumo Medical Corporation | $53.01 | 2 | 2025 |
Source payment records
|
|||||
| GLIDESHEATH SLENDER Normalized: glidesheath slender |
Device | Terumo Medical Corporation | $28.82 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $26.62 | 1 | 2025 |
Source payment records
|
|||||
| PROTEGE RX Normalized: protege rx |
Device | Medtronic, Inc. | $26.58 | 1 | 2025 |
Source payment records
|
|||||
| ELUVIA Normalized: eluvia |
Device | Boston Scientific Corporation | $25.81 | 1 | 2025 |
Source payment records
|
|||||
| Cohealyx Normalized: cohealyx |
Device | Avita Medical Americas, LLC | $25.18 | 1 | 2025 |
Source payment records
|
|||||
| Permeaderm Normalized: permeaderm |
Device | Avita Medical Americas, LLC | $25.18 | 1 | 2025 |
Source payment records
|
|||||
| Recell Normalized: recell |
Device | Avita Medical Americas, LLC | $25.18 | 1 | 2025 |
Source payment records
|
|||||
| ZENITH Normalized: zenith |
Device | Cook Medical LLC | $25.12 | 1 | 2025 |
Source payment records
|
|||||
| TORCON NB Normalized: torcon nb |
Device | Cook Medical LLC | $25.10 | 4 | 2025 |
Source payment records
|
|||||
| EVERFLEX PROTEGE EVERFLEX Normalized: everflex protege everflex |
Device | Medtronic, Inc. | $24.97 | 1 | 2025 |
Source payment records
|
|||||
| ANGIO-SEAL Normalized: angio seal |
Device | Terumo Medical Corporation | $24.19 | 1 | 2025 |
Source payment records
|
|||||
| NAVICROSS Normalized: navicross |
Device | Terumo Medical Corporation | $24.19 | 1 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy Normalized: pounce thrombectomy |
Device | Surmodics, Inc. | $18.41 | 1 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy System Normalized: pounce thrombectomy system |
Device | Surmodics, Inc. | $18.41 | 1 | 2025 |
Source payment records
|
|||||
| Pounce Venous Thrombectomy System Normalized: pounce venous thrombectomy system |
Device | Surmodics, Inc. | $18.41 | 1 | 2025 |
Source payment records
|
|||||
| Sublime 014 Rx PTA Balloon Dilatation Catheter Normalized: sublime 014 rx pta balloon dilatation catheter |
Device | Surmodics, Inc. | $18.41 | 1 | 2025 |
Source payment records
|
|||||
| Sublime Microcatheter, 018, 200cm, Straight Normalized: sublime microcatheter 018 200cm straight |
Device | Surmodics, Inc. | $18.41 | 1 | 2025 |
Source payment records
|
|||||
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| ALPHAVAC Normalized: alphavac |
Device | AngioDynamics, Inc. | $16.63 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 239 | 99 |
| Xarelto | Rivaroxaban | 89 | 18 |
| Cilostazol | Cilostazol | 73 | 31 |
| Bupropion Hcl Sr | Bupropion Hcl | 52 | 18 |
| Eliquis | Apixaban | 52 | 14 |
| Atorvastatin Calcium | Atorvastatin Calcium | 36 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 31 | 29 |
| Gabapentin | Gabapentin | 23 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 19 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 18 | suppressed |
| Prednisone | Prednisone | 13 | 12 |
| Ozempic | Semaglutide | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $10,003.70 · 85 records | Penumbra, Inc. | ABRE, ALPHAVAC, ANGIO-SEAL, ARTIX MT, AURYON LASER SYSTEM 100-120 VAC, AZUR CX DETACHABLE, Alto Abdominal Stent Graft System, Asahi Peripheral Vascular Wires, CLOTTRIEVER BOLD CATHETER, COLLAGENASE SANTYL, CT THROMBECTOMY SYSTEM KIT, Cohealyx, ELUVIA, ENDURANT IIS, ENROUTE Transcarotid Neuroprotection System, ESPRIT, EVERFLEX PROTEGE EVERFLEX, FLOWTRIEVER, FLOWTRIEVER CATHETER, S, GLIDESHEATH SLENDER, GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis, GORE TAG Conformable Thoracic Endoprosthesis, HAWKONE, Indigo System, Kerecis GraftGuide, Kerecis SurgiClose, NAVICROSS, Ozempic, PROTEGE RX, Permeaderm, Pounce Thrombectomy, Pounce Thrombectomy System, Pounce Venous Thrombectomy System, Recell, RotarexS 6 F x 135 cm, Rybelsus, SYMPHONY CATHETER, Sublime 014 Rx PTA Balloon Dilatation Catheter, Sublime Microcatheter, 018, 200cm, Straight, TORCON NB, Varithena Administration Pack, ZENITH | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error